27.01.2023 14:47:08

Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Dupixent, recommending expanded approval in the European Union to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy.

The positive CHMP opinion is supported by data from a Phase 3 trial in children 6 months to 5 years of age recently published in The Lancet, the company said.

In June 2022, Dupixent was approved by the FDA for children in this age group.

For More Such Health News, visit rttnews.com.

Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Regeneron Pharmaceuticals Inc. 672,00 -1,06% Regeneron Pharmaceuticals Inc.
Sanofi S.A. (spons. ADRs) 45,60 0,44% Sanofi S.A. (spons. ADRs)
Sanofi S.A. 91,06 -0,07% Sanofi S.A.